A novel predictive marker for placental abruption with composite adverse outcomes: creatinine–fibrinogen ratio

Purpose To develop a new cost-effective marker named creatinine–fibrinogen ratio (CFR) for the prediction of composite adverse outcomes (CAO) in placental abruption cases. Methods A total of 109 placental abruption patients (30 with adverse outcomes, 79 without adverse outcomes) were enrolled in this retrospective cohort study. Patients with at least one of the features listed below were included in the abruption with CAO group: requirement of blood product transfusion (erythrocyte suspension, fresh frozen plasma, pooled thrombocyte, thrombocyte apheresis), development of acute kidney injury or disseminated intravascular coagulation, and need for intensive care unit. Laboratory parameters and CFR values at admission to the hospital were compared between the two groups. Results Higher creatinine and lower fibrinogen levels were found in the CAO group ( p = 0.007 and p